Methods: We calculated the proportion of persons virally suppressed (<200 copies/mL at the last test in each of two 12–month measurement periods), pre- and post- model implementation. Included in the analysis were persons with ≥1 HIV viral load in each measurement period. McNemar’s test was used to compare the proportion virally suppressed, pre- and post- implementation. Multivariable logistic regression was used to determine factors associated with viral suppression, post-implementation. Participant demographics and the Proportion of Days Covered (PDC; a measure used to calculate adherence to medication therapy) were used as explanatory variables in the model. The PDC was modified to account for the time to the last viral load in the measurement period, and was stratified into four categories: ≥90%, <90-80%, <80-50%, and <50%.
Results: With 765 persons enrolled, the plurality of those included in the analysis (n=648) were non-Hispanic black (n=286), male (n=470), and had a median age of 49 years (IQR=38-56). Viral suppression improved 16.3% from 73.9% to 85.9%, pre- to post-implementation (p<0.001). Persons who had higher modified PDC (OR 1.9 per category level; 95% CI 1.4-2.6), were currently employed (OR 4.1; 1.6-12.8), or age >50 years (OR 4.7; 2.1-11.8), had greater odds of being suppressed. Non-Hispanic black persons were less likely to be suppressed (OR 0.2; 0.1-0.6); however, viral suppression among this group improved from 62.5% to 77.6%, pre- to post-implementation (p<0.001).
Collaborations between community pharmacists and HIV clinic providers that seek to identify and address HIV therapy-related problems can lead to improved viral suppression among persons living with HIV.
P. Clay, Jaguar Health, Inc.: Consultant and Speaker's Bureau , Consulting fee and Speaker honorarium . Merck & Co., Inc.: Investigator , Research grant .
T. Bush, None
A. Delpino, Walgreens: Employee and Shareholder , Salary .
M. Shankle, None
N. Camp, None
H. Kirkham, None
R. Hazen, None
P. Weidle, None